Executive Summary

The global medical technology (medtech) industry is undergoing structural transformation as multiple forces converge. China's evolving volume-based procurement (VBP) program is redefining pricing expectations worldwide, while the steady shift of procedures to ambulatory surgical centers (ASCs) is altering care delivery economics. Simultaneously, trade tensions and supply chain disruptions are forcing manufacturers to rethink global production footprints. The rapid adoption of GLP-1 receptor agonists is reshaping treatment pathways across metabolic and cardiovascular conditions, and enabling technologies—including robotics, imaging, navigation, and digital workflows—are driving competition toward platform-based ecosystems. This article analyzes these five critical trends, their global significance, strategic implications, and the outlook through 2030.

Introduction

For decades, medtech companies operated within relatively predictable market structures. Product innovation, regulatory approvals, and reimbursement decisions formed the core of competitive strategy. That era is ending. In 2026, the industry faces a confluence of policy shifts, economic pressures, and technological discontinuities that demand a more sophisticated approach to global markets, supply chains, and customer engagement.

Understanding how these forces interact is essential for executives, investors, healthcare providers, and public officials who depend on a resilient and innovative medical technology sector.

Background

The reference that anchors this analysis, Medtech Trends to Watch in 2026, published by Clarivate, identifies five key trends. These trends reflect not just incremental changes but fundamental shifts in how medical devices are priced, distributed, adopted, and integrated into clinical practice. They are amplified by geopolitical developments, demographic changes, and technological acceleration.

Main Analysis

1. China's VBP Expansion Redefines Global Market Economics

Mainland China's national volume-based procurement program has evolved from a cost-containment measure into a powerful market-shaping instrument. The latest VBP rounds introduce more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational medtech companies, participation in China is no longer a simple access opportunity; it is a strategic calculus involving portfolio selection, pricing architecture, and long-term competitive positioning.

The ripple effects of China's VBP extend well beyond its borders. Global pricing benchmarks, particularly in emerging markets, are increasingly influenced by expectations set in China. Multinationals are now compelled to design value propositions that can work within stringent procurement frameworks while preserving margins in other regions.

2. Outpatient and ASC Settings Become Central to Procedure Strategy

The migration of surgical procedures from hospitals to ambulatory surgical centers (ASCs) and other outpatient settings is accelerating. Regulatory changes, such as the U.S. Centers for Medicare & Medicaid Services (CMS) updates to the OPPS and ASC payment systems, are expanding the list of procedures eligible for outpatient care. This includes higher-acuity interventions like cardiac ablations, which were historically hospital-based.

For medtech manufacturers, this shift demands new commercial models. Product designs must accommodate the logistical and economic realities of ASCs, including lower overhead costs, shorter recovery times, and different purchasing decision-making processes. Companies that fail to adapt will lose relevance in a growing segment of the market.

3. Global Trade and Supply Chain Pressures Reshape Manufacturing Strategy

Tariffs, geopolitical tensions, and raw material cost volatility are compelling medtech companies to reposition their manufacturing strategies. Long-held assumptions about offshoring and single-source supply chains are being replaced by a focus on resilience, flexibility, and regionalization. Larger firms are leveraging scale to invest in multi-region footprints, while smaller players are revaluating their supplier relationships.

These pressures are not merely operational; they have strategic implications for cost structure, competitive advantage, and the ability to respond to market disruptions. The industry is moving from just-in-time to just-in-case manufacturing principles.

4. GLP-1 Therapies Shift Patient Behavior and Care Pathways

The widespread adoption of glucagon-like peptide-1 (GLP-1) receptor agonists is transforming the management of obesity and its comorbidities. These therapies are altering referral patterns for bariatric surgery, changing demand for continuous glucose monitors, and influencing the trajectory of sleep apnea and cardiovascular devices. The effect is uneven across procedure types, but its cumulative impact is becoming clear.

Medtech companies must now anticipate how pharmacological innovations alter the demand for devices across entire care pathways. This requires a more integrated view of metabolic disease management, where devices and pharmaceuticals coexist and compete.

5. Enabling Technologies Drive Platform-Based Competition

Robotics, imaging, navigation, and digital workflow tools are no longer optional add-ons; they are central to the competitive positioning of medtech firms. Integrated platforms that span clinical planning, execution, and postoperative care are becoming the cornerstone of service-line strategy. Companies are investing heavily in ecosystems that perpetuate customer lock-in and generate valuable data for continuous improvement.

Open-platform approaches are also emerging, offering flexibility and interoperability that challenge proprietary systems. This dynamic will likely intensify competition and accelerate innovation, but it also raises questions about data governance and cybersecurity.

Global Significance

The trends outlined above have profound implications beyond individual companies.

• Global economy: Pricing pressures in medtech affect healthcare spending across both advanced and emerging economies. Lower device costs may improve access, but they also impact the profitability of research-intensive industries.
• International trade: Supply chain realignment and tariff exposure are influencing broader trade patterns, particularly in high-technology manufacturing sectors.
• Public policy: Governments are becoming more proactive in shaping medtech markets through procurement, regulation, and reimbursement policies. The intersection of health policy and industrial policy is increasingly evident.
• Climate and sustainability: The shift to resilient supply chains includes pressure to reduce environmental footprint, creating opportunities for greener manufacturing and logistics.
• Innovation ecosystems: The rise of platform-based competition changes how innovation is funded and commercialized, potentially favoring large incumbents over startups unless open standards prevail.

Strategic Insights

• Portfolio optimization: Medtech companies must reassess their product portfolios in light of China's VBP and ASC migration. Divesting non-core assets or reengineering products for lower-cost settings may be necessary.
• Pricing sophistication: Global price referencing is making it difficult to sustain differentiated pricing. Companies need advanced analytics to model price-volume scenarios across multiple markets.
• Supply chain de-risking: Building regional manufacturing hubs, dual sourcing, and investing in digital supply chain monitoring are now strategic defenses against geopolitical volatility.
• Pharmaco-device integration: Partnerships with pharmaceutical companies, particularly around GLP-1 therapies, could become a source of new growth and competitive differentiation.
• Data and AI: Platform technologies generate large amounts of clinical data. Companies that harness AI to improve outcomes and operational efficiency will lead the next wave of innovation.

Future Outlook (2026–2030)

Over the next three to five years, these trends will evolve and amplify.

• China's influence will likely expand, not only in domestic procurement but as a model for other emerging economies seeking cost-containment. Multinationals will need to rethink their China strategies as the market becomes more contested.
• Outpatient care will continue to grow, with more complex procedures moving to ASCs and home-based care settings. Device miniaturization and remote monitoring will accelerate this shift.
• Supply chain regionalization will solidify, with an emphasis on resilience over cost efficiency. Tariff policy and geopolitical events could still disrupt progress, necessitating adaptive strategies.
• GLP-1 therapies may expand beyond metabolic and cardiovascular indications, potentially impacting neurological and inflammatory conditions. Their effect on procedures will vary, but Medtech companies must remain agile.
• Platform competition is likely to become the dominant business model. Open platforms may be the key to fostering innovation and preventing monopolistic lock-in, but they require robust data privacy and interoperability standards.

Additionally, the integration of artificial intelligence into clinical workflows will accelerate, driving further convergence between software and hardware. The competitive bifurcation between scale players and niche innovators will widen, with M&A activity likely to increase.

Conclusion

The medtech industry in 2026 stands at a crossroads. The forces outlined above are not cyclical but structural. Companies that embrace strategic transformation—rethinking pricing, portfolios, supply chains, care pathway alignment, and technology platforms—will be positioned to thrive. Those that remain anchored to legacy models risk being marginalized.

For policymakers and healthcare leaders, the challenge is to balance innovation incentives with affordability and access. The trends in this analysis provide a roadmap for understanding where the industry is headed and what is required to ensure its sustainable contribution to global health.

---

This article is based on the Clarivate report "Medtech Trends to Watch in 2026" and reflects independent editorial analysis of publicly available information.